Uvzszg Wart Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of common warts, which are characterized by a rough, cauliflower-like appearance.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Healthcare professionals are advised to follow the outlined procedure for the application of the medication to ensure optimal results.

The affected area should be washed thoroughly, and soaking in warm water for approximately 5 minutes may facilitate this process. After cleansing, the area must be dried completely to ensure proper adhesion of the medication.

A small amount of the medication should be applied directly to cover each wart. It is important to allow the application to dry completely before proceeding with any additional activities.

This application should be repeated twice daily as needed, with a maximum treatment duration of up to 12 weeks. Regular monitoring of the treatment area is recommended to assess the effectiveness and any potential side effects.

Contraindications

Use is contraindicated on irritated skin or reddened areas due to the potential for exacerbation of the condition. Additionally, the product should not be applied to individuals with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects.

Application is also contraindicated on birthmarks, warts with hair growth, or moles, as these may present unique risks that could lead to complications.

Warnings and Precautions

For external use only; contact with the eyes should be strictly avoided. In the event of accidental exposure to the eyes, it is imperative to rinse thoroughly with water for a minimum of 15 minutes.

Healthcare professionals should advise patients to avoid inhaling vapors associated with this product. In cases of ingestion, immediate medical assistance should be sought, or the individual should contact a Poison Control Center without delay.

Patients are encouraged to discontinue use and consult a healthcare provider if discomfort persists. Additionally, it is crucial for individuals who are pregnant or breastfeeding to seek guidance from a health professional prior to using this product to ensure safety for both the mother and child.

Side Effects

Patients should be aware that the product is intended for external use only and must be kept away from the eyes. In the event of contact with the eyes, it is recommended to rinse thoroughly with water for at least 15 minutes. Additionally, patients are advised to avoid inhaling vapors associated with the product.

In clinical practice, if discomfort persists after using the product, patients should discontinue use and consult a healthcare professional for further guidance. This precaution is essential to ensure the safety and well-being of individuals using the product.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Uvzszg Wart Remover (salicylic acid 17% wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is essential to evaluate the potential risks and benefits in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is no available data regarding the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical evaluation is recommended. Healthcare professionals should assess the patient's vital signs and conduct a thorough clinical examination. Supportive care should be initiated as necessary, which may include airway management, intravenous fluids, and monitoring of vital parameters.

If specific antidotes or treatments are available for the substance involved, they should be administered according to established protocols. Consultation with a poison control center or toxicology expert may also be warranted to guide management decisions.

It is crucial to document all findings and interventions in the patient's medical record and to report any adverse events to the appropriate regulatory authorities as required.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical help or contact a Poison Control Center if the product is swallowed.

Patients should be informed about the importance of avoiding application on irritated skin, reddened areas, or on individuals with diabetes or poor blood circulation. Additionally, they should not apply the product on birthmarks, warts with hair growth, or moles.

Healthcare providers should instruct patients to discontinue use and consult a doctor if discomfort persists after application.

For patients who are pregnant or breastfeeding, it is essential to recommend consulting a health professional before using the product to ensure safety for both the patient and the child.

Storage and Handling

The product is supplied in a tube that must be kept tightly closed when not in use to maintain its integrity. It should be stored at room temperature, away from direct light to prevent degradation. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

The medication is administered topically and may be applied twice daily as needed for a duration of up to 12 weeks. Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use.

No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Uvzszg Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)